While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...